Kazia Therapeutics IPO-Jahr
Was ist das IPO-Jahr von Kazia Therapeutics?
IPO-Jahr von Kazia Therapeutics Limited ist 1994
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Kazia Therapeutics
Was macht Kazia Therapeutics?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Unternehmen mit ipo-jahr ähnlich Kazia Therapeutics
- Sinopec Shanghai Petrochemical Co hat IPO-Jahr von 1993
- Delaware Investments Minnesota Municipal Income Fund II Inc hat IPO-Jahr von 1993
- Delaware Investments Colorado Insured Municipal Income Fund Inc hat IPO-Jahr von 1993
- Western Asset Municipal Partners Fund Inc hat IPO-Jahr von 1993
- Nuveen Maryland Quality Municipal Income Fund hat IPO-Jahr von 1993
- Enel Americas SA hat IPO-Jahr von 1993
- Kazia Therapeutics hat IPO-Jahr von 1994
- Hanover Insurance Inc hat IPO-Jahr von 1995
- Atlanticus Corp hat IPO-Jahr von 1995
- Integra Lifesciences Corp hat IPO-Jahr von 1995
- Telkom Indonesia (Persero) Tbk PT hat IPO-Jahr von 1995
- Myriad Genetics hat IPO-Jahr von 1995
- Redwood Trust hat IPO-Jahr von 1995